Bako Diagnostics (“BakoDx”) recently confirmed that the company experienced a data breach resulting in the personal and health information of certain consumers being compromised. If you received a ...

Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics continues to build upon its laboratory services platform both ...

ATLANTA, July 24, 2018 /PRNewswire/ -- Bako Diagnostics, a podiatry-focused clinical laboratory and products company, announced today the appointment of Ted Hull as Chief Executive Officer, effective ...

Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised tech-based laboratory services and therapeutic development company Fulgent Genetics’ on its $55.5 million acquisition of pathology and ...

Fulgent Genetics, Inc. FLGT recently entered into an agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx — two well-known pathology testing companies — in a combined ...